In this review, the authors present data supporting allogeneic HCT as a therapeutic option for patients with non-Hodgkin lymphoma (NHL) diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma focusing on patients over age 60. They note that recent advances in conventional lymphoma therapy, peri-transplant supportive care, patient selection, and donor selection (including the use of alternative hematopoietic cell donors), have allowed broader application of allogeneic HCT to NHL patients. The authors conclude that the research literature “strongly supports the concept that allo-HCT should be offered to fit patients well beyond age 65.
Fenske TS, et al. Biol Blood Marrow Transplant